{"id":"eplerenone-morning","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Hyperkalemia"},{"rate":"3-5","effect":"Dizziness"},{"rate":"2-4","effect":"Fatigue"},{"rate":"1-3","effect":"Abdominal pain"},{"rate":"1-2","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eplerenone selectively inhibits aldosterone binding to mineralocorticoid receptors, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the collecting duct. This leads to increased sodium and water excretion, reduced blood volume and blood pressure, and decreased cardiac fibrosis and remodeling. Unlike non-selective aldosterone antagonists, eplerenone has minimal affinity for other steroid receptors, reducing hormonal side effects.","oneSentence":"Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:39.746Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction left ventricular dysfunction"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT06649409","phase":"PHASE1","title":"Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2024-06-05","conditions":"Pharmacodynamic","enrollment":30},{"nctId":"NCT01955694","phase":"PHASE2","title":"Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-11","conditions":"Heart Failure","enrollment":72},{"nctId":"NCT00515021","phase":"PHASE4","title":"Diurnal Variation of Plasminogen Activator Inhibitor-1","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2007-04","conditions":"Metabolic Syndrome X","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inspra"],"phase":"marketed","status":"active","brandName":"Eplerenone (Morning)","genericName":"Eplerenone (Morning)","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss. Used for Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}